Cas9 Stable Cell Line - HTR-8/SVneo

The Cas9 Stable Cell Line - HTR-8/SVneo is an immortalized human trophoblast cell line derived from placental tissue in early pregnancy. This cell line was initially established through transfection with simian virus 40 large T antigen (SV40 TAg), preserving key characteristics of extravillous trophoblast cells, including invasiveness and hormone secretion. The Cas9-stable cell line—HTR-8/SVneo—is a genetically engineered variant in which the CRISPR-associated protein 9 (Cas9) endonuclease is stably integrated into the genome. Parental HTR-8/SVneo cells exhibit epithelial-like morphology, express trophoblast-specific markers (such as cytokeratin-7 and HLA-G), and demonstrate robust proliferative capacity, making them ideal for placental research. Cas9 modification enables precise genome editing while preserving the biological relevance of the original cell line in mimicking early pregnancy development.

The Cas9 Stable Cell Line - HTR-8/SVneo provides a powerful platform for functional genomics and disease modeling in reproductive biology. Researchers have used it for high-throughput CRISPR screening to identify genes regulating trophoblast cell invasion, proliferation, and differentiation—processes crucial for placental establishment and disrupted in pathological conditions such as preeclampsia and fetal growth restriction. Stable Cas9 expression simplifies knockout/knock-in studies of pregnancy-related genes (such as FLT1, ENG, or HIF pathway components) by avoiding transfection variability. Furthermore, this cell line can aid in studying the mechanisms of maternal-fetal interface interactions, including trophoblast cell responses to oxidative stress, hypoxia, or immunomodulators. Its pharmaceutical applications include screening for therapeutics against placental dysfunction and assessing the toxicity of compounds during pregnancy.